Perifosine

Drug Profile

Perifosine

Alternative Names: AEZS-104; D-21266; KRX-0401; NSC-639966; Perifosin; YHI-1003

Latest Information Update: 21 Apr 2017

Price : $50

At a glance

  • Originator AEterna Zentaris Inc
  • Developer AEterna Zentaris Inc; Yakult Honsha
  • Class Antineoplastics; Quaternary ammonium compounds; Radiosensitisers; Small molecules; Trimethyl ammonium compounds
  • Mechanism of Action Proto oncogene protein c-akt inhibitors; Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroblastoma; Multiple myeloma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Glioma; Gynaecological cancer
  • No development reported Neuroblastoma; Solid tumours
  • Discontinued Chronic lymphocytic leukaemia; Colorectal cancer; Gastrointestinal stromal tumours; Leukaemia; Lymphoma; Multiple myeloma; Non-small cell lung cancer; Renal cell carcinoma; Sarcoma; Waldenstrom's macroglobulinaemia

Most Recent Events

  • 01 Mar 2017 Memorial Sloan Kettering Cancer Center completes a phase I trial in Solid tumours (Combination therapy, Second-line therapy or greater, In infants, In children, In adolescents, In adults) in USA (NCT01049841)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuroblastoma(In children, Monotherapy) in USA (PO, Tablet)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Neuroblastoma(Second-line therapy or greater) in Japan (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top